Tempest Therapeutics, Inc. Restructuring and Related Cost, Number of Positions Eliminated
Tempest Therapeutics, Inc. (TPST) had Restructuring and Related Cost, Number of Positions Eliminated of 21 Employees as of 2025-04-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes
us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated · last filed 2026-08-13
- 2025-04-30: Restructuring and Related Cost, Number of Positions Eliminated 21.00 Employees.
| Period end | Restructuring and Related Cost, Number of Positions Eliminated |
|---|---|
| 2025-04-30 | 21.00 Employees 10-Q · filed 2026-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |